Ravoxertinib (GDC-0994)

1453848-26-4

ERK

MAPK

CN1C (=CC=N1) NC2=NC=CC (=N2) C3=CC (=O) N (C=C3) C (CO) C4=CC (=C (C=C4) Cl) F

C21H18ClFN6O2

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

2 years -80 in solvent